Account Executive
BiorenderSalary not specified
- Full Time
- Mid-level (3 to 4 years)
About Biorender
BioRender provides an online platform for creating scientific illustrations tailored for the life sciences field. Users can access thousands of pre-drawn icons and templates covering over 30 life sciences disciplines, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform's user-friendly interface enables clients, including academic researchers, pharmaceutical companies, and educational institutions, to create figures for research papers, presentations, and educational materials with minimal effort. BioRender operates on a subscription model, offering various plans to suit different user needs, including enterprise solutions for larger organizations. The company's goal is to simplify the process of creating high-quality scientific illustrations, making it an essential resource for effective scientific communication.
Toronto, CanadaHeadquarters
2017Year Founded
$16.7MTotal Funding
SERIES_ACompany Stage
Biotechnology, Education, HealthcareIndustries
201-500Employees
Benefits
Remote Work Options
Flexible Work Hours
Risks
AI-driven design tools may reduce demand for BioRender's platform.
Increased competition from cheaper visualization platforms could erode market share.
Potential IP disputes over pre-drawn icons could lead to legal challenges.
Differentiation
BioRender offers a vast library of customizable icons and templates for scientists.
The platform provides a user-friendly interface for creating professional scientific figures.
BioRender serves diverse clients, including academia, biotech, and pharmaceutical companies.
Upsides
Increased demand for digital communication boosts need for scientific visualization tools.
Growing interest in graphical abstracts enhances research visibility and accessibility.
Open-access publishing trend increases demand for high-quality, appealing figures.
Funding
Total raised$16.74 M
Latest valuation$85.20 M
StageSERIES_A
SERIES A
3/31/2023$17
$85.20 MSEED
12/31/2017N/A
$500.0 K